This website uses cookies
Read our Privacy policy and Terms of use for more information.
Jul 23, 2026
Novo sues Lilly over Zepbound advertising, Repligen buys BioLife for $1.5B, and Big Pharma embraces psychedelic medicines.
Jul 21, 2026
Samsung Biologics makes a $1.8B peptide acquisition, Lilly expands into psychedelics, Merck launches the first oral PCSK9 drug, and Kalshi brings betting to clinical trials.
Jul 16, 2026
Chai Discovery reaches a $3.8B valuation as biotech enters earnings season alongside major AI deals, FDA approvals and billion-dollar licensing agreements.
Jul 14, 2026
Cyclospora spreads across 31 states, Sanofi earns a first-of-its-kind FDA approval, and five emerging biotech hubs challenge Boston and San Francisco.
Jul 9, 2026
Xaira steps into the spotlight, Vertex spends $10 billion, and investors continue pouring money into select biotech winners.
Jul 7, 2026
Hair loss becomes biotech's hottest investment theme while AI companies inch closer to competing with Big Pharma.
Jul 2, 2026
Claude Science enters the lab, Orca Bio wins FDA approval, and Congress investigates pharma's clinical trial activity in China.
Jun 30, 2026
Moderna launches its first in vivo CAR-T, Merck makes an $11B acquisition, and FDA reversals could reshape rare disease approvals.
Jun 25, 2026
White House denies Trump received Lilly's experimental GLP-1 retatrutide as AbbVie, Lilly and Evaluate reshape biotech's outlook.
